View : 16 Download: 0

A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer

Title
A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
Authors
Ning G.Zhu Q.Kang W.Lee H.Maher L.Suh Y.-S.Michaud M.Silva M.Kwon J.Y.Zhang C.Lee C.
Ewha Authors
Charles Lee
SCOPUS Author ID
Charles Leescopus
Issue Date
2021
Journal Title
BMC Cancer
ISSN
1471-2407JCR Link
Citation
BMC Cancer vol. 21, no. 1
Keywords
And MAPK pathwayCRISPR/Cas9 screeningGastric cancerHER2 amplificationLapatinib resistancePI3K pathway
Publisher
BioMed Central Ltd
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Background: Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Human epidermal growth factor receptor 2 (HER2) amplification occurs in approximately 13–23% of all GC cases and patients with HER2 overexpression exhibit a poor prognosis. Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, is an effective agent to treat HER2-amplified breast cancer but it failed in gastric cancer (GC) clinical trials. However, the molecular mechanism of lapatinib resistance in HER2-amplified GC is not well studied. Methods: We employed an unbiased, genome-scale screening with pooled CRISPR library on HER2-amplified GC cell lines to identify genes that are associated with resistance to lapatinib. To validate the candidate genes, we applied in vitro and in vivo pharmacological tests to confirm the function of the target genes. Results: We found that loss of function of CSK or PTEN conferred lapatinib resistance in HER2-amplified GC cell lines NCI-N87 and OE19, respectively. Moreover, PI3K and MAPK signaling was significantly increased in CSK or PTEN null cells. Furthermore, in vitro and in vivo pharmacological study has shown that lapatinib resistance by the loss of function of CSK or PTEN, could be overcome by lapatinib combined with the PI3K inhibitor copanlisib and MEK inhibitor trametinib. Conclusions: Our study suggests that loss-of-function mutations of CSK and PTEN cause lapatinib resistance by re-activating MAPK and PI3K pathways, and further proved these two pathways are druggable targets. Inhibiting the two pathways synergistically are effective to overcome lapatinib resistance in HER2-amplified GC. This study provides insights for understanding the resistant mechanism of HER2 targeted therapy and novel strategies that may ultimately overcome resistance or limited efficacy of lapatinib treatment for subset of HER2 amplified GC. © 2021, The Author(s).
DOI
10.1186/s12885-021-08283-9
Appears in Collections:
자연과학대학 > 생명과학전공 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE